Drugs Exam 4 Flashcards
(123 cards)
1
Q
Neurohumoral modulation drugs to reduce “afterload”
A
- ACE inhibitors and AII-receptor blockers
- Anti-adrenergic agents (ß-blockers)
- Mineralocorticoid Receptor Antagonists
- ARB-Neprilysin inhibitors (EntrestoTM)
- Drugs that alter cGMP (nitrates and vericiguat (VerquovoTM).
2
Q
MOA of Entresto
A
- combination of an ARB “Valsartan” and sacubitril (an inhibitor of the peptidase neprilysin)
- Neprilysin mediates enzymatic degradation and inactivation of natriuretic peptides (ANP, BNP, CNP), bradykinin, and substance P.
3
Q
Entresto combines inhibition of the ____ with activation of a beneficial ______________
A
RAAS; neurohumoral activation, the natriuretic peptides.
4
Q
clinical effects of ARNi
A
- promote the beneficial effects natriuresis, diuresis, and vasodilation of arterial and venous blood vessels.
- inhibit thrombosis, fibrosis, cardiac myocyte hypertrophy, and renin release
5
Q
how do ARNI augment BNP/ANP levels?
A
by inhibiting their degradation, which is a better pharmacological principle than giving the solely the agonist BNP (neseritide)
6
Q
T/F: Clinicians choose Entresto over ACE/ARBI.
A
Sort of but no
Entresto is recommended over an ACE inhibitor or ARB in patients with NYHA Class II or III HF
However, some clinicians recommend reserving Entresto for patients who remain symptomatic on optimal doses of an ACEI or an ARB.
7
Q
adverse effects of Entresto
A
- Hypotension, renal insufficiency, and hyperkalemia can occur.
8
Q
what should be monitor for patients taking Entresto?
A
BP and serum K+
9
Q
Patients taking with a history of what should not have taking Entresto
A
with a history of angioedema should not take an ARNI
10
Q
drug interactions of Entresto
A
- contraindicated for use with or within 36 hours after the last dose of an ACE inhibitor.
- Concurrent use of potassium-sparing diuretics
- NSAIDs might worsen renal function
- Contraindicated in Pregnancy (ARB)
11
Q
___ patients with heart failure with ___________ should receive what?
A
ALL; reduced ejection fraction; ACEI/ARB
12
Q
how should ACEI/ARB be administered?
A
start at low doses and titrate to the highest tolerated dose targeting the maximum daily dosages listed in the table
13
Q
how do we improve fluid retention?
A
Diuretics may be combined with ACEI and ARB’s
14
Q
T/F: Diuretics that act on the DCT are more effective in the treatment of HF than loop of Henle.
A
FALSE: Diuretics that act on the loop of Henle are more effective in the treatment of HF than thiazide diuretics.
15
Q
side effects of ACEI
A
- Hypotension
- Cough
- Hyperkalemia
- because they reduce aldosterone, which normally mediates Na+ absorption and K+ excretion
- Proteinuria and angioedema
- Contraindicated: Pregnancy
16
Q
side effects of ARB
A
- Hypotension
- Recommended for patients with cough from ACEI
- Less angioedema Than ACEI
- Contraindicated: Pregnancy
17
Q
ACEI and ARBS ______ actions of AII on the heart, __, and kidney
A
antagonize deleterious; BV (blood volume)
18
Q
ACEI and ARB do what to the vein and arteries?
A
dilation to decrease the mean arterial BP
19
Q
effect of aldosterone levels of ACEI and ARBS
A
reduce levels - acts as an indirect diuretic
20
Q
T/F: ARBS and ACEI decrease stroke volume and cardiac output for a given preload
A
False, they INCREASE
21
Q
ACEI and ARBS ______ ventricular end-diastolic pressure and volume
A
reduce
22
Q
do ACEI and ARBS increase or decrease bradykinin?
A
INCREASE - cough (common SE)
23
Q
T/F: ACEI/ARBS improve myocardial energy metabolism
A
TRUE
24
Q
what kind of B blocker is Carvedilol?
A
non-selective with no ISA
HOWEVER, also alpha-1 adrenergic blocker
25
what drug is a scavenger of oxygen free radicals?
Carvedilol
Purpose: role in myocardial necrosis
26
clinical effects of Carvediolol
* **_increases_** S.V. decreases intracardiac and pulmonary vascular pressure
* **_decreases_** heart rate
* prevents **_enlargement_** of the left ventricle.
* **_Reduces_** incidence of diabetes mellitus
27
metoprolol clinical effects
same as Carvediolol
* **_increases_** S.V. decreases intracardiac and pulmonary vascular pressure
* **_decreases_** heart rate
* prevents **_enlargement_** of the left ventricle.
* **_Reduces_** incidence of diabetes mellitus
28
metoprolol CR/XL compared to carvedilol
* Better because…
* Once a day dosing
* Less **_hypotension_** because *α1-antagonism* of carvedilol may result in more orthostatic hypotension.
* **_More selective_** *ß1- blockade* that may reduce the risk of bronchospasm.
29
disadvantages of metoprolol CR/XL
* Its metabolism is dependent on polymorphic CYP2D6.
* CYP2D6 *“poor metabolizers,”* about 8% of _Caucasians_, exhibit CPmax levels of metoprolol 5-fold higher than those of standard metabolizers.
30
how is bisoprolol different than other B blockers?
* Unlike carvedilol and metoprolol this drug is **not metabolized by the CYP2D6** system.
* Has a long-half life and is given once daily.
31
side effects of B blockers
* may aggravate heart failure in some patients.
* Therefore, they are administered at low doses that are built slowly
* contraindicated in asthma
32
what is the only drug that is approved as an add-on drug for HF?
***_eplenorone_***
33
MOA aldosterone antagonists
* **_Antagonists_** of nuclear receptors of *aldosterone*.
* Aldosterone, as the second major actor of the RAAS, promotes Na+ and fluid retention, loss of K+ and Mg2+ , and myocardial and vascular fibrosis and damage.
* Additional efficacy in suppressing the consequences of *neurohumoral activation*
34
what is Aldosterone escape?
Aldosterone plasma levels decrease under therapy with ACEIs or ARBs, but quickly increase again
35
side effects of aldosterone antagonists
hyperkalemia
36
T/F: the addition of a MRA (Mineralocorticoid Receptor Antagonist) is recommended for ___ patients with NYHA Class ____ heart failure.
ALL; II-IV (2-4)
37
when do you not use a MRA?
* Do not use if the GFR is less than 30 mL/min (creatinine ~ 2 mg/dL).
* Be careful with diabetics, who carry a higher risk of hyperkalemia.
* Combination with
* NSAIDs, which are contraindicated in heart failure but are frequently prescribed for chronic degenerative diseases of the musculoskeletal system
* other K+-sparing diuretics.
38
MOA of vericgiuat
* potent soluble guanylate cyclase stimulator
* reduces after load by increasing cGMP leading to smooth muscle relaxation and vasodilation of veins/arteries
39
what is vericiguat intended for
use in adults with symptomatic chronic HF and EF who are receiving standard therapy without further symptom improvement
40
side effects and contraindications vericiguat
contraindicated pregnancy
PDE5 inhibitors (i.e. Viagra) - hypotension
41
MOA hydralazine
relaxes arteriolar smooth muscles
42
combine hydralazine with ??
diuretic, isosorbide mono- or dinitrate and occasionally with an ACEI
43
Bidil
Combo isosorbide dinitrate + hydralazine
is the first **_race-based drug_** in the US, because it is marketed exclusively for *CHF* in *African Americans*
44
effects of hydralazine
* ***_Reduces_*** systemic and vascular resistance
* ***_Reduces_*** R and L ventricular afterload
* ***_Increases_*** stroke volume and reduces stress during ventricular systole.
* Has ***_no effect_*** on venous capacitance, used with a ***nitrovasodilator*** for HFrEF patients.
45
MOA Nitroglycerin, Isosorbide Dinitrate, Isosorbide monitrate
activate soluble guanylyl cyclase by *mimicking* the activity of nitric oxide (NO)
46
effects of Nitroglycerin, Isosorbide Dinitrate, Isosorbide monitrate
* ***_Increase_*** concentration of cyclic GMP in vascular smooth muscles relaxes smooth muscles in peripheral veins
* ***_Increase_*** venous capacitance
* ***_Improve_*** exercise capacity
* ***_Reduce_*** pulmonary and systemic vascular resistance
47
side effects of nitroglycerin, Isosorbide Dinitrate, Isosorbide monitrate
* ntirate tolerance
* hypotension
48
what do positive inotropic medications do?
* increase strength of heart muscle contraction
* increase SV
* increase CO
49
what is a digitalis glycoside
digoxin
50
MOA of digoxin
1. Binds to and **inhibits** the a-subunit of the sarcolemma Na+-K+- ATPase.
2. Inhibition of the ATPase leads to an **increase** in intracellular *Na+* *concentration* which in turn activate Na+/Ca++ exchange leading to **increased** intracellular *Ca++ concentration.*
3. Increased Ca++ ions are reabsorbed by the S.R. Therefore, the **concentration of Ca++ in the S.R. increases**
51
digoxin inotropic effects
positive - caused by increase Ca2+ ion during systole
* **Increase** the velocity of cardiac muscle shortening.
* **Increased** stroke volume is generated for a given preload.
52
digoxin sympathetic activity
* direct: *Inhibit Na-K-ATPase in neuronal cells.* Stimulate parasympathetic and inhibit sympathetic discharges.
* indirect: Improve the pattern of fluctuating sympathetic discharges because digitalis *sensitizes pressure sensitive baroreceptor cells.*
53
digoxin electrophysiological effects
* **Prolong** the effective *refractory period*
* **Decrease** conduction velocity the AV node.
* **Increase** in vagal tone impedes transmission through the AV node.
54
does digoxin improve survival?
No
* decreases symptoms of heart failure,
* increases exercise tolerance,
* decreases the rate of hospitalization
55
pharmacokinetics of digoxin
* Extensively distributed in the tissues, as reflected by the large volume of distribution.
* The half-life of elimination varies between 26 and 45 hours
* ***_Impaired kidney function_*** is the most important condition with an influence on the pharmacokinetics of digoxin.
56
how often do you measure serum digoxin?
once because many factors may influence the sensitivity of the myocardium to digoxin
57
Factors that increase the toxicity of digitalis
* **_Narrow margin of safety_** (monitor digoxin serum levels).
* **_Hypokalemia_** – hypokalemia enhances digitalis toxicity by *promoting glycoside* binding to the Na+-K+-ATPase pump and by inhibiting the turnover of the Na+ pump.
* Hypokalemia decreases the margin of safety of digitalis glycosides.
58
extracardiac side effects of digitalis
* CNS: visual problems, fatigue
* G.I.: Anorexia, nausea and vomiting
59
cardiac side effects of digitalis
Electrophysiological, including suppression of AV conduction, ectopic beats in AV and ventricle. EKG reveals a prolonged PR interval
60
Treatment of Digoxin intoxication
* Administration of K+:
* potassium stimulates sodium pump activity, reduces glycoside binding to the Na+-K+-ATPase and alters membrane conductance to cations.
* Anticardiac glycoside immunotherapy ***(Digibind™)***
* Digibind™ is a purified preparation of Fab fragments from sheep anti-digoxin antisera.
* 1 vial neutralizes 0.6 mg digoxin
61
what is dopamine used for
Used for short-term support of the circulation in heart failure
62
MOA of dopamine
activates cardiac ß1-adrenergic receptors (cardiotonic) and *dopamine receptors in the kidney to produce renal vasodilatation.*
63
where is dopamine, dobutamine, amrinone, milirinone generally used
hospitals
64
clinical uses of dopamine
* maintenance of B.P. in cardiogenic,
* hemorrhagic or
* other types of shock
65
general MOA for catecholamines
* **Activates the β1-adrenergic receptor**
* Activation of cardiac β1-adrenergic receptor promotes the *elevation* of cyclic AMP which in turn activates a cyclic AMP-dependent protein kinase that phosphorylates the calcium channel.
* The phosphorylated calcium channel becomes more *permeable* to calcium and therefore *catecholamines increase calcium influx through the sarcolemma* and also stimulate the Ca2+ pump of the S.R. resulting in an *increase* in calcium uptake by the S.R.
* Therefore, **more calcium can be released from the S.R. during systole.**
66
MOA dobutamine
it has a wider spectrum than dopamine and stimulates both **β1- and β2-adrenergic receptors and also both a1- and a2-adrenergic receptors**.
67
effects of dobutamine
* *Positive inotropic effects* due to activation of β1-AR
* Does not increase renal blood flow selectively like dopamine
* Acts as a **vasodilator** and
* **Reduces** vascular resistance
68
why is dobutamine selected over dopamine?
superior to Dopamine in patients with advanced heart failure who do not improve with oral vasodilators
69
MOA of amirnone and milirinone ("none")
* Cyclic AMP is degraded to AMP by “phosphodiesterases”.
* By inhibiting the PDE, cAMP is preserved to produce its effects on contractility.
70
how is milrinone “better” than amrinone?
* 10 times more potent
* shorter half-life and is
* more selective for type III PDE than Amrinone.
71
can you use PDE III long term?
NO
## Footnote
Used for short-term only because long-term use of these drugs often causes *intolerable side effects and increased death among heart failure patients.*
72
MOA ivabradine
* Inhibits cardiac pacemaker current (If), a mixed sodium-potassium inward current (funny current).
* Slows firing in the SA node, and ultimately **_reduces_** heart rate.
* Its cardiac effects are specific to the ***_SA node with no BP effects._***
73
indications of ivabradine
* 2nd line drug
* for symptomatic heart failure, LVEF ≤35%, and a resting heart rate \>70 bpm despite beta blocker therapy.•
* Reduced rates of hospitalization and death due to heart failure, but **not** *cardiovascular death,* compared to placebo
74
side effects ivabradine
Mild and infrequent
luminous phenomena (phosphenes) or visual brightness because ivabradine partially inhibits the retinal current
75
MOA of empaglifozin
inhibit the sodium-glucose co-transporter in the proximal convoluted tubule
76
empaglifozin is also used for?
used to ***lower*** blood glucose levels in patients with type II *_diabetes →_* by increasing the urinary excretion of glucose
77
In patients with type 2 diabetes and established cardiovascular disease, addition of ________ to standard treatment reduced not only the risk of hospitalization for HF, MACE from any cause and progression of renal disease.
empagliflozin
78
what is angina?
a lack of sufficient oxygen (ischemia) to the heart that causes pain
79
why does angina occur?
* Coronary artery obstruction limits blood supply to part of the myocardium
80
what is unstable angina?
Atherosclerosis (blocked by a plaque) and thrombosis blocks blood flow (unstable angina)
Recurrent angina associated with minimal exertion
Prolonged and frequent pain
Thought to be due to fissuring of atherosclerotic plaques and subsequent platelet aggregation
81
high association with myocardial infarction and \_\_\_\_\_\_
unstable angina
82
what is variant (vasospastic, Prinzmetal's) angina?
* vasospasm blocks blood flow
* A direct result of reduction in coronary flow due to vasospasm, not an increase in myocardial oxygen demand
83
what is the prognosis for variant angina?
excellent prognosis
84
what do angiograms look like in variant angina?
normal
85
what is exertional (exercise-induced) angina?
Coronary circulation can meet _oxygen demands_ of myocardium at rest, but not when heart work increased by exercise (exertional angina)… due to ***atherosclerosis.***
usually due to fixed coronary vascular obstruction (surgical revascularization or angioplasty may be beneficial)
86
approaches to treating angina
1. Increase coronary blood flow (Nitrates, CCB)
2. Reduce myocardial oxygen consumption (mvo2) by:
3. Prevent platelet deposition/aggregation: *aspirin*
4. Coronary artery bypass surgery and eluting stents
87
how do you reduce myocardial oxygen consumption (3)?
1. NEGATIVE ***CHRONOTROPIC*** EFFECT: decreased heart rate
2. NEGATIVE ***INOTROPIC*** EFFECT: myocardial contractility
3. Decreased ventricular workload (wall stress):
1. Reduced preload (venodilation)
2. Reduced afterload (vasodilation)
88
MOA of nitrates
venodilation (veins) = decreased preload
vasodilation (arteries) = decreased afterload
89
effects of nitrates
* BP: unchanged or slight decrease
* HR: unchanged or slight increase.
* Pulmonary Vascular Resistance: decreased
* Cardiac Output: reduced (slight)
90
adverse effects of nitrates
hypotension
headache
drug rash
91
important drug interaction with nitrates
do not take sildenafil (Viagra)/type V PDE
92
tolerance of nitrates
continuous nitrate exposure leads to loss of efficacy
which is why you want 8-12 hours of “nitrate-free” interval each day
93
MOA of non-dihydropyridine
* decreased heart rate
* decreased myocardial contractility
* slowed AV conduction
* Reduces MvO2 by reducing heart rate, contractility, afterload
* ***Prevents or reverses vasospasm (coronary vasodilation)***
94
non-dihydropyridine
Verapamil
Diltiazem
95
MOA of dihydropyridine
* More potent vasodilators = reflex cardiac stimulation
* Direct and indirect effects balanced
* Heart rate, myocardial contractility usually unchanged
* AV node conduction unaffected
* Reduces MvO2 by reducing afterload
* Primary mechanism of antianginal effect: ***reduced afterload, coronary vasodilation***
96
when to use CCB dihydropyridine-type in angina
* In combination with ß-Blocker for coronary vasodilation, reduced afterload.
* Avoid Verapamil/Diltiazem + β-Blocker… AV block
* Sinus bradycardia, SA/AV block
* Valvular Insufficiency (Aortic, Mitral): reduces afterload
97
contraindicated with B blockers (anti-anginals)
di-hydro
98
when to use CCB non-dihydropyridine-type in angina
* Asthma/Bronchospastic COPD (cannot use beta-blockers)
* Severe Peripheral Vascular Disease with rest pain Depression
* Labile (variable glucose levels) insulin dependent diabetes
99
MOA of B blockers (antianginals)
reduce heart rate and inotropic response to exercise - prevent reflex tachycardia
\*reduce afterload (NOT preload)
does NOT prevent coronary vasospasm
100
drug of choice for angina
drug of choice
101
T/F: CCB’s reserved for use in patients unable to tolerate β-blocker or as add-on therapy for angina uncontrolled by β-blocker + nitrate
TRUE
102
Cardiac effects (β1AR) are responsible for therapeutic effects:
* reduce resting heart rate, myocardial contractility
* attenuate increased heart rate, contractility in response to exercise
* reduces myocardial oxygen consumption
103
(β2AR) are responsible for many adverse effects of β-blockers including…
* Bronchospasm
* Hypoglycemia
* Lethargy, confusion, nightmares
* Alopecia (hair loss)
104
B blockers contraindications
* Sinus bradycardia,
* SA/AV block
* decompensated CHF,
* Labile or "brittle" Diabetes (can swing “wildly” in both directions),
* Asthma,
* COPD\*
105
can you stop B blockers?
Yes, but NOT abruptly.
## Footnote
Abrupt withdrawal of ß-blocker may induce rebound tachycardia, unstable angina or MI!!!
106
unstable angina treatment
B blockers + nitrates, aspirin and heparin
107
B blocker effects in exertional angina
reduces HR, myocardial contractility
108
are B blockers effective in vasoplastic angina
ineffective
109
what do give in acute MI/unstable angina
give ß-blocker IV following by PO therapy provided no CHF, hypotension, or sinus bradycardia/heart block
110
Ranolazine (Ranexa)
Selective late-sodium current inhibitor with nitric oxide effects on HR or BP
111
verapamil
class IV antiarrhythimics
more cardioselective
more potent antiarrhythimics
112
diltiazem
class IV antiarrhythimics
more effective vasodilator
better antihypertensive
113
when do you use ranolazine?
**chronic stable** angina in combination with amlodipine, ß-blockers or nitrates
(adjunct therapy)
114
adverse reactions of ranolazine
* Dizziness, headache, constipation, nausea
* Syncope and asthenia
115
contraindications of ranolazine
* Concurrent use of **CYP3A4 inhibitors** (grape fruit juice, verapamil, diltiazem and others)
* Use of **tricyclic antidepressants,** fluoxetine, Haldol, nefazodone.
* **Digoxin concentrations** increase 40-60% through p-glycoprotein inhibition.
* **Pregnancy** category C
116
what drug has the lowest IC50
ranolazine
lowest concentration to have its effects
117
summary nitrates
coronary vasodilation
reduced after load (aterial)
reduced preload (venous)
118
summary non dihydro-P
| (Verapamil, Diltiazem)
coronary vasodilation
reduced HR
decreased contraction force
reduced afterload
119
summary dihydro-P
| ("dipines")
coronary vasodilation
reduced afterload
120
summary of beta-blocker
reduced heart rate
decreased contractile force
reduced after load
121
MOA of antiarrhythmics
block Na+, K+, Ca2+ channels in a state-dependent manner (block at inactive/active state NOT resting)
bind to active or inactive channels than resting channels
prolong the time required for channels to recover from inactivation and recycle back to the resting state
selectively inhibit cells that are firing at abnormally fast rates
122
ECG of quinidine
* decrease conduction velocity
* decrease automaticity
* increase ERP in fast response fibers
* also blocks some K+ channels to prolong phase 3
* stretching EKG
123
MOA quinidine
* reduces Vmax in frequency-dependent manner
* blocks ***_ACTIVATED_*** Na+ channels
* slows recovery of Na+ channels
* has local anesthetic properties that manifest as reduction in membrane responsiveness
